N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer
Oropharyngeal Dysphagia · Oropharyngeal Cancer
Primary: Optimal Respiratory - Swallow Phase — 43; 86; 88.1 percentage of swallows
N/A N=10 A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Aerodigestive Tract Cancer · Lung Cancer · Esophageal Cancer
Primary: Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat — 67; 40; 40 percentage of change
Phase 2 N=45 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
Head and Neck Cancer · Precancerous/Nonmalignant Condition
Primary: Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment — 32 participants
N/A N=170 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
Head and Neck Cancer · Oropharyngeal Cancer · Hypopharyngeal Cancer
Primary: Number of Participants With Adequate Exposure and Access to Oropharyngeal and Hypopharyngeal Head and Neck Lesions — 147; 23 participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
N/A N=49 Clinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in Oropharyngeal Head and Neck Cancer
Head and Neck Cancer · Dysphagia
Primary: Modified Barium Swallow Impairment Profile (MBSImP) Pharyngeal Total (PT) Score — 11.00; 12.33; 9.84; 10.73 score on a scale
Phase 2 N=19 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Head and Neck Cancer · Precancerous Condition
Primary: Number of Participants With Objective Response Based on Histologic Grade — 13; 6 Participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
N/A N=26 Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
Non-small Cell Lung Carcinoma · Small Cell Lung Carcinoma
Primary: Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE) — 0 Participants
Phase 2 N=30 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Oral Cancer
Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants
Phase 2 N=4 Trimodality Management of T1b Esophageal Cancers
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
N/A N=50 Esophageal Cytology With FISH in Detecting Esophageal Cancer
Dysphagia · Dysplasia · Esophageal Adenocarcinoma
Primary: Sensitivity of Sponge Cytology Using FISH — 13.3 percentage of cases among positive tests
Phase 2 N=110 Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
Esophageal Cancer
Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants
Phase 2 N=65 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 1 N=9 A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Cancer of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Cancer of the Stomach
Primary: Maximum Tolerated Dose of Vandetanib — 100 milligrams
N/A N=7 Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Esophageal Cancer
Primary: Dose of Radiation Delivered to 90% of Tumor Volume (D90) — 105.5 percentage of Prescription dose
Phase 2 N=21 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=40 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Response Rate — 37 Participants
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
N/A N=22 Proton Radiotherapy for Upper Gastrointestinal Malignancies
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Phase 2 N=34 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants
Phase 2 N=43 Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Phase 2 N=22 Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
Esophageal Cancer
Primary: Overall Survival — 7.3 months
Phase 2 N=6 Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Resectable Esophageal Cancer · GastroEsophageal Cancer
Primary: Number of Participants With Dose Limiting Toxicity — 0 Participants
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Phase 2 N=74 Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants